Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Operating Leases (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Operating Leases for 5 consecutive years, with $26.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 14.77% to $26.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $26.7 million, a 14.77% decrease, with the full-year FY2024 number at $30.3 million, up 41.09% from a year prior.
  • Operating Leases was $26.7 million for Q3 2025 at Lyra Therapeutics, down from $27.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $33.4 million in Q1 2024 to a low of $3000.0 in Q2 2022.
  • A 5-year average of $13.4 million and a median of $3.0 million in 2021 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: tumbled 99.68% in 2022, then skyrocketed 162800.0% in 2023.
  • Lyra Therapeutics' Operating Leases stood at $379000.0 in 2021, then soared by 75.99% to $667000.0 in 2022, then soared by 3115.44% to $21.4 million in 2023, then skyrocketed by 41.09% to $30.3 million in 2024, then fell by 11.78% to $26.7 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Operating Leases are $26.7 million (Q3 2025), $27.9 million (Q2 2025), and $29.1 million (Q1 2025).